Peptide library › Metabolic & weight
Lixisenatide
Also known as Adlyxin, Lyxumia, Soliqua (with insulin glargine)
Once-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
What people use it for
- Type 2 diabetes, especially blood sugar after meals
What Lixisenatide does in the body
A short-acting GLP-1 receptor agonist based on exendin-4. Its strongest effect is slowing stomach emptying, which blunts the rise in blood sugar after meals, alongside boosting insulin and lowering glucagon.
Strength of evidence
Strong: the GetGoal trial programme, and the ELIXA heart safety trial, which found no increase in heart risk.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and vomiting
- Low blood sugar when combined with insulin or sulfonylureas
- Allergic reactions (rare)
Who should avoid it or take extra care
- History of pancreatitis
- Severe stomach-emptying problems (gastroparesis)
- Pregnancy or breastfeeding, unless a specialist advises it
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2016. The stand-alone Adlyxin pen was discontinued in the US in 2023; it remains available combined with insulin glargine as Soliqua.
How it's taken
Route: Injection under the skin, once daily before a meal
How long it lasts (half-life): About 3 hours
Latest research & news
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Clinical trial · Active not recruiting · Updated · ClinicalTrials.gov · 20 Nov 2026 - Incretin-Based Therapies and the Gut-Brain Axis in Neurodegenerative Diseases
Research · Review · PubMed · Mol Neurobiol · 17 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Lixisenatide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Lixisenatide in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- AmycretinExperimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- PemvidutideExperimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- Insulin analogsLab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
- GlucagonEmergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.
- DasiglucagonStable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.